2.1 Study design
We conducted an observational cohort study that evaluated the results of a 16-gene PGx panel test and their implementation for personalized pharmacotherapy. The primary outcome of the study was the proportion of patients where PGx panel testing had clinically relevant management implications for current or potential future medication.
The study protocol was reviewed and approved by the local ethics board (EKNZ project ID 2020-00565), and all included patients had signed informed consents for PGx testing and scientific use of their health data.